Loading...
•
Dec 31, 2025
Liquidia Q4 2025 Earnings Report
Liquidia reported strong initial commercial traction from YUTREPIA and achieved its second consecutive quarter of profitability following the product’s launch in mid-2025.
Key Takeaways
Liquidia generated $92021000 in revenue in Q4 2025 driven primarily by YUTREPIA product sales following its commercial launch earlier in the year. The company reported net income of $14555000 and positive operating income of $19787000, marking the second consecutive profitable quarter.
Quarterly revenue reached $92021000 driven mainly by YUTREPIA product sales.
Net income was $14555000, representing the company’s second consecutive profitable quarter.
Operating income totaled $19787000 reflecting strong commercial launch economics.
Cash and cash equivalents ended the year at $190680000 supporting continued commercialization and clinical programs.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Management expects continued growth from the commercial rollout of YUTREPIA while investing in further clinical development and expanding prescriber adoption across pulmonary hypertension indications.
Positive Outlook
- YUTREPIA achieved strong adoption with more than 3600 prescriptions since launch.
- More than 2900 patients have started treatment since commercialization began.
- The company achieved a second consecutive quarter of profitability.
- Cash balance of $190680000 provides financial flexibility.
- Further clinical studies and expanded sales force planned to support growth.
Challenges Ahead
- Commercial success remains heavily dependent on YUTREPIA as the primary revenue driver.
- Ongoing litigation related to YUTREPIA could impact commercialization.
- R&D investments remain necessary to advance pipeline programs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...